Misplaced Pages

LY-2109761

Identifiers
IUPAC name 4-pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine
CAS Number	700874-71-1
PubChem CID	11655119
CompTox Dashboard (EPA)	DTXSID30470111
Chemical and physical data
Formula	C26H27N5O2
Molar mass	441.535 g·mol
3D model (JSmol)	Interactive image
SMILES C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6
InChI InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2 Key:IHLVSLOZUHKNMQ-UHFFFAOYSA-N

LY-2109761 is a synthetic compound which acts as a potent and selective inhibitor for the growth factor receptor TGF beta receptor 1. It is used for research into conditions such as pulmonary fibrosis and cancer.

See also

• Galunisertib
• GW788388

References

1. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. (April 2008). "LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis". Molecular Cancer Therapeutics. 7 (4): 829–840. doi:10.1158/1535-7163.MCT-07-0337. PMC 3088432. PMID 18413796.
2. Tan QY, Cheng ZS (2018). "TGFβ1-Smad Signaling Pathway Participates in Interleukin-33 Induced Epithelial-to-Mesenchymal Transition of A549 Cells". Cellular Physiology and Biochemistry. 50 (2): 757–767. doi:10.1159/000494241. PMID 30308508. S2CID 52966340.

This article needs additional or more specific categories. Please help out by adding categories to it so that it can be listed with similar articles. (August 2022)

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Kinase inhibitors
• Pharmacology stubs